Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Elisabeth Ng, Jonathan E. Shaw, Anna Wood, Louise J. Maple-Brown, Matthew JL Hare

Research output: Contribution to journalArticlepeer-review


Background Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D.

Original languageEnglish
Pages (from-to)513-518
Number of pages6
JournalAustralian journal of general practice
Issue number7
Publication statusPublished - Jul 2022


Dive into the research topics of 'Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes'. Together they form a unique fingerprint.

Cite this